Daiichi Sankyo And Merck Report Patritumab Deruxtecan Showed Statistically Significant Progression-Free Survival Improvement In EGFR-Mutated Non-Small Cell Lung Cancer Population
Portfolio Pulse from Benzinga Newsdesk
Daiichi Sankyo and Merck's phase 3 trial of patritumab deruxtecan shows significant improvement in progression-free survival for EGFR-mutated NSCLC patients. The trial met its primary endpoint, with overall survival data still being assessed.
September 17, 2024 | 10:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck, in collaboration with Daiichi Sankyo, reported positive results from a phase 3 trial of patritumab deruxtecan, showing significant progression-free survival improvement in EGFR-mutated NSCLC patients.
The positive trial results for patritumab deruxtecan, a drug co-developed by Merck, indicate potential future success in treating EGFR-mutated NSCLC, which could boost investor confidence and positively impact Merck's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80